ArticleOpen forum infectious diseases2020

Treatment Switch to Dolutegravir With 2 Nucleoside Reverse-Transcriptase Inhibitors (NRTI) in Comparison to Continuation With Protease Inhibitor/Ritonavir Among Patients With Human Immunodeficiency Virus at Risk for Prior NRTI Resistance: A Cohort Analysis of Real-World Data.

Mohamed N'dongo Sangaré et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.